Shanghai Best-link Bioscience, Llc
Clinical trials sponsored by Shanghai Best-link Bioscience, Llc, explained in plain language.
-
New hope for lung cancer that outsmarts first-line drugs
Disease control Not yet recruitingThis study tests a new drug, BL0020, in 48 adults whose lung cancer changed from non-small cell to small cell after initial targeted therapy. The drug aims to shrink tumors and control the disease. Participants must have this specific cancer transformation and meet other health c…
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Best-Link Bioscience, LLC • Aim: Disease control
Last updated May 17, 2026 01:02 UTC
-
New hope for tough lung cancer? early trial combines two drugs to fight recurrence.
Disease control Not yet recruitingThis early-stage study tests a new drug (BL0020) combined with an immunotherapy (Toripalimab) in about 33 adults with extensive-stage small cell lung cancer that returned after initial treatment. The main goal is to find a safe dose and see if the combo can shrink tumors. This is…
Phase: PHASE1 • Sponsor: Shanghai Best-Link Bioscience, LLC • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New drug BL0175 tested for safety in postmenopausal women
Knowledge-focused Not yet recruitingThis early-stage study tests a single dose of a new drug called BL0175 in 27 postmenopausal women to see if it is safe and how long it stays in the body. It compares BL0175 to an existing drug, fulvestrant. The main goal is to check for side effects and measure drug levels in the…
Phase: PHASE1 • Sponsor: Shanghai Best-Link Bioscience, LLC • Aim: Knowledge-focused
Last updated May 12, 2026 13:40 UTC